Find a Tribute
Search all personal tribute pages to donate in a loved one’s name.
Find a Fundraiser
Find a Fundraiser
Year-round, hundreds of events and initiatives across the country (and virtually) raise funds crucial to support our mission to cure ovarian and related gynecologic cancers. Whether these are personal tributes honoring loved ones, OCRA’s signature fitness fundraisers, or custom events created by our imaginative, passionate supporters, there are many ways to get involved.
Looking for an OCRA fundraiser?
Click on a category below or email events@ocrahope.org for assistance.
Ovarian Fitness Fundraisers
Support someone participating in an official Ovarian Cycle or Ovarian Fitness event or bring an event to your community.
Read more about Ovarian Fitness Fundraisers Make your workout work
Find a Personal Fundraiser
Know someone hosting their own Run/Walk community event or birthday party, celebrating a milestone, or dedicating their race participation to OCRA? Find them here.
Read more about Find a Personal Fundraiser Support a personal fundraiser
Related Topics
OCRA President & CEO Audra Moran Named Crain’s 2026 Notable Leader in Health Care
Audra Moran, President and CEO of Ovarian Cancer Research Alliance (OCRA), has been recognized as a Crain’s New York Business 2026 Notable Leader in Health Care. Crain’s annual recognition spotlights health care executives whose leadership, innovation, and community commitment set a high bar for the field. Honorees are selected based on demonstrated impact, both within … Continued
OCRA Sponsors NCCN Guidelines for Cervical, Ovarian, and Uterine Cancer Patients
This article was updated in April 2026 to reflect NCCN’s release of the 2026 Guidelines for Uterine Cancer Patients. OCRA is a proud sponsor of the 2026 Patient Guidelines for Cervical Cancer and Uterine Cancer, and the 2025 Patient Guidelines for Ovarian. We believe ensuring access to clear, understandable information is critical. NCCN provides wonderful … Continued
FDA Approves Lifyorli Plus Abraxane for Platinum-Resistant Ovarian Cancer
On March 25, 2026, the U.S. Food and Drug Administration (FDA) approved Lifyorli (relacorilant), made by Corcept Therapeutics, in combination with Abraxane (nab-paclitaxel) for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior lines of treatment, including prior Avastin (bevacizumab). The approval follows last month’s FDA … Continued